Cellectra Reports Positive Phase 2 CLOVER Trial Data for Iopofosine I 131 in Waldenstrom Macroglobulinemia

Cellectra announced positive topline results on June 2, 2026, from its Phase 2 CLOVER trial evaluating iopofosine I 131 in patients with relapsed or refractory Waldenstrom macroglobulinemia, a rare blood cancer. The study met its primary endpoint, demonstrating a clinically meaningful overall response rate. The data showed that 71% of patients achieved a response, including a major response rate of 56%, according to the company. The treatment was generally well-tolerated, with a safety profile consistent with previous studies. Cellectra plans to submit a new drug application to the U.S. Food and Drug Administration in the second half of 2026. The company will host a conference call to discuss the data.